OnKure is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancer. The company uses a structure-based drug design platform to build tumor-agnostic candidates designed for optimal efficacy and tolerability. Its pipeline includes bocodepsin (OKI-179), an oral selective Class I HDAC inhibitor for hematological and solid tumors, and OKI-219, a selective PI3K alpha H1047R inhibitor. OnKure announced it closed a $54 million Series C financing to support continued development of its next-generation precision medicines. Proceeds will be used to advance OKI-219 into clinical development, and the company said it expects to file a second IND in 2023. The company is based in Boulder, Colorado. OnKure is a Boulder, CO–based biopharmaceutical company focused on epigenetics-driven drug discovery and development. Its core programs are targeted small molecule candidates intended to improve outcomes for cancer patients. The company aims to treat cancer by targeting malignant cells and circulating lymphocytes, altering the tumor microenvironment to optimize checkpoint inhibition, and delaying kinase inhibitor resistance. OnKure’s most advanced programs target Class-1 histone deacetylase (HDAC) enzymes as well as HDAC6. Led by co-founder, President & CEO Tony Piscopio, the company is advancing research and development across these programs. OnKure completed a financing to accelerate its R&D activities.

Total raised

$61M

Funding rounds

2

Latest round

Series C

Latest activity

May 2023